The diabetic, hypertensive heart: Epidemiology and mechanisms of a very high-risk situation

Journal of Human Hypertension

Volumn 23, Issue 11, 2009, Pages 709-717

  Franjic, B ^a   Marwick, T H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINA PECTORIS; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; METABOLIC DISORDER; MICROALBUMINURIA; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HEART; HUMANS; HYPERTENSION; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 70350271416     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.43     Document Type: Review

References (91)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: A general population study. Br Med J 1989; 299: 1127-1131.
3. Tenenbaum A, Fisman EZ, Boyko V, Goldbourt U, Auerbach I, Shemesh J et al. Prevalence and prognostic significance of unrecognised systemic hypertension in patients with diabetes mellitus and healed myocardial infarction and/or stable angina pectoris. Am J Cardiol 1999; 84: 294-298.
4. Janghorbani M, Hu FB, Willett WC, Li TY, Manson JE, Logroscino G et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes; The Nurses' Health Study. Diabetes Care 2007; 30: 1730-1735.
5. Goff DC, Zaccaro DJ, Haffner SM, Saad MF. Insulin sensitivity and the risk of incident hypertension: Insights from the Insulin Resistance Atherosclerosis Study. Diabetes Care 2003; 26: 805-809.
6. Salonen JT, Lakka TA, Lakka H, Valkonen V, Everson SA, Kaplan GA. Hyperinsulinaemia is associated with the incidence of hypertension and dyslipidaemia in middle-aged men. Diabetes 1998; 47: 270-276.
7. Barr ELM, Magliano DJ, Zimmet PZ, Polkinghorne KR, Atkins RC, Dunstan DW et al. AusDiab 2005: The Australian Diabetes, Obesity and Lifestyle Study - tracking the accelerating epidemic: Its causes and outcomes. International Diabetes Institute: Melbourne, Australia. http://www.diabetes.com.au/pdf/AUSDIAB_Report_Final.pdf (accessed 28/02/ 09) P11.
8. Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care 2003; 26: 2910-2914.
9. Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE et al. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med 2001; 161: 242-247.
10. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: A population-based retrospective cohort study. Lancet 2006; 368: 29-36.
11. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective trials. Lancet 2002; 360: 1903-1913.
12. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562.
13. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance, The Whitehall Study. Lancet 1980; 315: 1373-1376.
14. Tenenbaum A, Fisman EZ, Boyko V, Goldbourt U, Graff E, Shemesh J et al. Hypertension in diet versus pharmacologically treated diabetics: mortality over a 5-year follow-up. Hypertension 1999; 33: 1002-1007.
15. The Hypertension in Diabetes Study Group. II Increased risk of cardiovascular complications in hypertensive type diabetic patients. J Hypertens 1993; 11: 319-325.
16. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713-1724.
17. Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J 2007; 28: 3059-3066.
18. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. Br Med J 2000; 321: 412-419.
19. Zhang Y, Lee ET, Devereux RB, Yeh J, Best LG, Fabitz RR et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: The Strong Heart Study. Hypertension 2006; 47: 410-414.
20. Hu G, Sarti C, Jousilhati P, Peltonen M, Qiao Q, Antikainen R et al. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke 2005; 36: 2538-2543.
21. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347: 797-805.
22. Hasslacher C, Stech W, Wahl P, Ritz E. Blood pressure and metabolic control as risk factors for nephropathy in Type 1 (insulin-dependent) diabetes. Diabetologia 1985; 28: 6-11.
23. Oakley WG, Pyke DA, Tattersall RB, Watkins PJ. Long-term diabetes: A clinical study of 92 patients after 40 years. Q J Med 1974; 169 145-156.
24. The Hypertension in Diabetes Study Group. I Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovacular and diabetic complications. J Hypertens 1993; 11: 309-317.
25. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. Br Med J 2008; 337: A918.
26. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. Ann Intern Med 1988; 108: 7-13.
27. Antikainen R, Grodzicki T, Palmer AJ, Beevers DG, Coles EC, Webster J et al. The determinants of left ventricular hypertrophy defined by Sokolow-Lyon criteria in untreated hypertensive patients. J Hum Hypertens 2003; 17: 159-164.
28. Dunn FG, McLanachan J, Isles CG, Brown I, Dargie HJ, Lever AF et al. Left ventricular hypertrophy and mortality in hypertension: An analysis of data from the Glasgow blood pressure clinic. J Hypertens 1990; 8: 775-782.
29. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 1994; 90: 179-185.
30. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355-1364.
31. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264-272.
32. Boon D, Piek JJ, van Montfrans GA. Silent ischaemia and hypertension. J Hypertens 2000; 18: 1355-1364.
33. Lubaszewski W, Kawecka-Jaszcz K, Czarnecke D, Rajzer M, Stochmal A. Silent myocardial ischaemia in patients with essential arterial hypertension and non-insulin dependent diabetes mellitus. J Hum Hypertens 1999; 13: 309-313.
34. Indermuhle A, Vogel R, Meier P, Wirth S, Stoop R, Mohaupt MG et al. The relative blood volume differentiates between hypertensive heart disease and athlete's heart in humans. Eur Heart J 2006; 27: 1571-1578.
35. Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93.
36. Brush JE, Cannon RO, Schenke WH, Bonow RO, Leon MB, Maron BJ et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 1988; 319 1302-1307.
37. Opherk D, Mall G, Zebe H, Schwarz F, Weihe E, Manthey J et al. Reduction of coronary reserve: A mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation 1984; 69: 1-7.
38. van Hoeven KH, Factor SM. Endomyocardial biopsy diagnosis of small vessel disease: A clinicopathologic study. Int J Cardiol 1990; 26: 103-110.
39. Mayet J, Hughes A. Cardiac and vascular pathophysiology in hypertension. Heart 2003; 89: 1104-1109.
40. Palmieri V, Belle JN, Roman MJ, Gerdts E, Papademetriou V, Watchell K et al. Pulse pressure/stroke index and left ventricular geometry and function: The LIFE Study. J Hypertens 2003; 21: 781-787.
41. Mottram PM, Haluska BA, Leano R, Carlier S, Case C, Marwick TH. Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease. Heart 2005; 91: 1551-1556.
42. Kesavan S, Edmond J, Finch D, Baumbach A. Severity of coronary artery disease at presentation in patients with diabetes mellitus - an observational study of 14770 patients. Eur Heart J 2008; 29: 468.
43. Jokl R, Laimins M, Klein RL, Lyons TJ, Lopes-Virella MF, Colwell JA. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care 1994; 17: 818-823.
44. Geisler T, Anders N, Bischofs C, Rapin M, Schoelzel B, Bigalke B et al. Type II diabetes is associated with increased residual platelet aggregation in patients receiving dual antiplatelet therapy after coronary stent implantation. ePoster ESC Congress 2008. http://spo.escardio.org/eslides/view.aspx?eevtid=24&id=2876 (accessed 28/02/09).
45. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
46. Fang ZY, Yuda S, Anderson V, Short L, Case C, Marwick TH. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 2003; 41: 611-617.
47. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK et al. Impact of diabetes on cardiac structure and function: The Strong Heart Study. Circulation 2000; 101: 2271-2276.
48. Boyer JK, Thanigaraj S, Schechtman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004; 93: 870-875.
49. Galderisi M, Capaldo B, Sidiropoulos M, D'Errico A, Ferrara L, Turco A et al. Determinants of reduction of coronary flow reserve in patients with type 2 diabetes mellitus or arterial hypertension without angiographically determined epicardial coronary stenosis. Am J Hypertens 2007; 20: 1283-1290.
50. Pitkanen OP, Nuutila P, Raitakari OT, Ronnemaa T, Koskinen PJ, Iida H et al. Coronary flow reserve is reduced in young men with IDDM (insulin-dependent diabetes mellitus). Diabetes 1998; 47: 248-255.
51. Moir S, Hanekom L, Fang ZY, Haluska B, Wong C, Burgess M et al. Relationship between myocardial perfusion and dysfunction in diabetic cardiomyopathy: A study of quantitative contrast echocardiography and strain rate imaging. Heart 2006; 92: 1414-1419.
52. Fang ZY, Najos-Valencia O, Leano R, Marwick TH. Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine. J Am Coll Cardiol 2003; 42: 446-453.
53. Galderisi M, de Simone G, Innelli P, Turco A, Turco S, Capaldo B et al. Impaired inotropic response in type 2 diabetes mellitus: A Strain Rate Imaging Study. Am J Hypertens 2007; 20: 548-555.
54. Semeniuk LM, Kryki AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 2002; 283: H976-H982.
55. Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH et al. Activation of PPAR-gamma enhances myocardial glucose utilisation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 2005; 289: E328-E336.
56. Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2006; 47: 598-604.
57. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004; 109: 2191-2196.
58. 2+-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 2002; 51: 1166-1171.
59. Scognamiglio R, Casara D, Avogaro A. Myocardial dysfunction and adrenergic innervation in patients with Type 1 diabetes mellitus. Diabetes Nutr Metab Clin Exp 2000; 13: 346-349.
60. Kahn JK, Zola B, Juni JE, Vinik AI. Decreased exercise heart rate and blood pressure response in diabetic subjects with cardiac autonomic neuropathy. Diabetes Care 1986; 9: 389-394.
61. Tedesco MA, Natale F, Di Salvo G, Caputo S, Capasso M, Calabro R. Effects of coexisting hypertension and type II diabetes mellitus on arterial stiffness. J Hum Hypertens 2004; 18: 469-473.
62. Jain A, Avendano G, Dharamsey S, Dasmahaptra A, Agarwal R, Reddi A et al. Left ventricular diastolic function in hypertension and role of plasma glucose and insulin: Comparison with diabetic heart. Circulation 1996; 93: 1396-1402.
63. Govind S, Brodin LA, Nowak J, Quintana M, Raumina S Ramesh SS et al. Isolated type 2 diabetes mellitus causes myocardial dysfunction that becomes worse in the presence of cardiovascular diseases: (MYDID) Study 1. Cardiology 2005; 103: 189-195.
64. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990; 82: 848-855.
65. Rizzoni D, Palombo C, Porteri E, Muiesan ML, Kozakova M, La Canna G et al. Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients. J Hypertens 2003; 21: 625-631.
66. Rizzoni D, Porteri E, Boari GEM, De Ciuceis C, Sleiman I, Muiesan ML et al. Prognostic significance of small-artery structure in hypertension. Circulation 2003; 108: 2230-2235.
67. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A et al. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 2001; 103: 1238-1244.
68. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P et al. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996; 28: 785-790.
69. Rizzoni D, Porteri E, Guelfi D, Piccoli A, Castellano M, Pasini G et al. Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension 2000; 35: 931-935.
70. King GL, Goodman D, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulin like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985; 75: 1028-1036.
71. Kamide K, Hori MT, Zhu JH, Takagawa Y, Barrett JD, Eggena P et al. Insulin and insulin-like growth factor-1 promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 2000; 18: 1051-1056.
72. Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A et al. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991; 9: 17-22.
73. Prior JO, Quinones MJ, Hernandez-Pampaloni M, Facta AD, Schindler TH, Sayre JW et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 2005; 111: 2291-2298.
74. Taddei S, Virdis A, Mattei P, Arzilli F, Salvetti A. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992; 20(Suppl 12): 193-195.
75. Grunfeld B, Balzareti M, Romo M, Giminez M, Gutman R. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 1994; 23(Suppl I): I12-I15.
76. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784.
77. Vollenweider P, Randin D, Tappy L, Jequier E, Nicod P, Scherrer U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest 1994; 93: 2365-2371.
78. Baron AD, Bretchel-Hook G, Johnson A, Hardin D. Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 1993; 21: 129-135.
79. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31: 68-72.
80. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DASG. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108: 3097-3101.
81. Bevan RD. Trophic effects of peripheral adrenergic nerves on vascular structure. Hypertension 1984; 6(Suppl 3): 19-26.
82. Patel MB, Stewart JM, Loud AV, Anversa P, Wang J, Fiegel L et al. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 1991; 84: 2091-2100.
83. Sen S, Tarazi RC, Khairallah PA, Bumpus FM. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 1974; 35: 775-781.
84. Crespo MJ, Moreta S, Gonzalez J. Cardiovascular deterioration in STZ-diabetic rats: Possible role of vascular RAS. Pharmacology 2003; 68(1): 1-8.
85. Zhuo JL. Monocyte chemoattractant protein-1: A key mediator of angiotensin II-induced target organ damage in hypertensive heart disease. J Hypertens 2004; 22: 451-454.
86. Hu FB, Stampfer MJ. Is type 2 diabetes mellitus a vascular condition? Arterioscler Thromb Vasc Biol 2003; 23: 1715-1716.
87. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int 2000; 75(Suppl): 7-14.
88. Turner R, Holman R, Stratton I, Cull C, Frighi V, Manley S et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1988; 317 703-713.
89. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
90. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). Royal College of Physicians: London 2008. http://www.nice.org.uk/nicemedia/pdf/CG66diabetesfullguideline.pdf (accessed 28/02/09) p152.
91. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M et al. Weight loss and the renin-angiotensin=aldosterone system. Hypertension 2005; 45: 356-362.